Osimertinib in Untreated <i>EGFR</i> -Mutated Advanced Non–Small-Cell Lung Cancer

Soria, Jean‐Charles; Ohe, Yuichiro; Vansteenkiste, Johan; Reungwetwattana, Thanyanan; Chewaskulyong, Busyamas; Hyeong Lee, Ki; Dechaphunkul, Arunee; Imamura, Fumio; Nogami, Naoyuki; Kurata, Takayasu; Okamoto, Isamu; Zhou, Caicun; Chul Cho, Byoung; Cheng, Ying; Kyung Cho, Eun; Jye Voon, Pei; Planchard, David; Su, Wu‐Chou; E. Gray, Jhanelle; Ming Lee, Siow; Hodge, Rachel; Marotti, Marcelo; Rukazenkov, Yuri; S. Ramalingam, Suresh

doi:10.1056/nejmoa1713137

Public

Osimertinib in Untreated EGFR -Mutated Advanced Non–Small-Cell Lung Cancer

Published in New England Journal of Medicine • Nov 18, 2017

Authors:

Jean‐Charles Soria

Yuichiro Ohe

Johan Vansteenkiste

Abstract

BACKGROUND: Osimertinib is an oral, third-generation, irreversible epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) that selectively inhibits both EGFR-TKI-sensitizing and EGFR T790M resistance mutations. We compared osimertinib with standard EGFR-TKIs in patients with previousl...

Subject

Osimertinib

Lung cancer

Oncology

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!